Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Wion RK, Hill NL, DePasquale N, Mogle J, Whitaker EB. The relationship between subjective cognitive impairment and activity participation: a systematic review. Act Adapt Aging. 2020;44(3):225-45. doi: 10.1080/01924788.2019.1651188
Oser SM, Stuckey HL, Parascando JA, McGinley (Miller) EL, Berg A, Oser TK. Glycated hemoglobin differences among blog-reading adults with type 1 diabetes compared with those who do not read blogs: cross-sectional study. JMIR. 2019 Apr 2;4(2):e13634. doi: 10.2196/13634
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Oser TK, Oser SM, McGinley (Miller) EL, Stuckey HL. A novel approach to identifying barriers and facilitators in raising a child with type 1 diabetes: qualitative analysis of caregiver blogs. JMIR. 2017 Oct 26;2(2):e27. doi: 10.2196/diabetes.8966
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Porter W, Mahajan P, Danysh HE, Chelius DC. Socioeconomic determinants of pediatric papillary thyroid cancer: a SEER database review. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 21, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A135-6.
Mahajan P, Danysh HE, Chelius DC, Venkatramani R. Characteristics and outcomes of children and adolescents with low-risk papillary thyroid carcinoma in the SEER database. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 20, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A92.
Mahajan P, Danysh HE, Chelius DC, Venkatramani R. Characteristics and outcomes of children and adolescents with high-risk papillary thyroid carcinoma in the SEER database. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 20, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A92-3.
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.